Executive Teams of Emerging Biotech Companies Present to Investor Community
For Immediate Release
September 1, 2015
SAN DIEGO, CA – WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference. The Newsmakers conference is hosted annually by BioCentury and will take place at the Millennium Broadway Hotel and Conference Center in New York City on Thursday, September 10, 2015.
BioCentury’s NewsMakers conference allows emerging biotechnology companies to help identify investment and partnering prospects. The objective of the NewsMakers conference is to provide pharmaceutical executives, investment funds, and venture capitalists a venue to connect with investor-validated, milestone-rich private and public companies in key therapeutic areas for potential investment and partnership opportunities. NewsMakers in the Biotech Industry is recognized as the industry’s key venue for companies to take their story to Wall Street each fall.
Since 1993, BioCentury Publications, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury’s Editorial and Research staff comprises industry-recognized business and science editors and writers. The Company’s management team includes executives with backgrounds in international business, publishing, finance, and the biotech and pharmaceutical industries.
WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional clients and high net worth individuals.
The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. Our investment bank has participated in over 120 transactions leading to $4 billion placed. Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain. Our firm has been singled out for its equity research and analytics year after year from our peers for performance by the financial industry’s most highly regarded rankings organizations.